Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

US biotech Grove Biopharma has secured $30 million in a series A round to move its lead program targeting advanced prostate ...

Recent US news is marked by upheaval in governmental bodies and key policy shifts. This includes significant firings in the ...

A middle school student north of Dallas has tested positive. Meanwhile, Illinois has confirmed its first case in the state. Plus: A study in mice shows that covid is still contagious a week or more ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

US biopharma Novavax (Nasdaq: NVAX) closed 20% higher on Wednesday after announcing an update on its COVID-19 vaccine. The US ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Novavax’s vaccine, which is the only protein-based COVID-19 vaccine, is awaiting for its full approval. Once approved, it ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...